REPORT ON A PROSPECTIVE-STUDY IN RECOMBINANT ERYTHROPOIETIN SUPPLEMENT THERAPY DURING CHEMOTHERAPY IN PATIENTS WITH MALIGNANT BONE-TUMORS

被引：0
|
作者：
WURNIG, C [1 ]
WINDHAGER, R [1 ]
SCHWAMMEIS, E [1 ]
KOTZ, R [1 ]
机构：
[1] UNIV VIENNA,A-1010 VIENNA,AUSTRIA
来源：
TRANSFUSION | 1993年 / 33卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S75 / S75
页数：1
相关论文
共 40 条
  • [31] The influence of low molecular weight heparin on the intravascular activation of the coagulation system in patients with acute leukemia during induction chemotherapy - Report of a prospective randomized study
    Chojnowski, K
    Trelinski, J
    Wawrzyniak, E
    Robak, T
    LEUKEMIA & LYMPHOMA, 2002, 43 (05) : 1021 - 1028
  • [32] Recombinant human interleukin-1 beta: new possibilities for the prophylaxis and correction of toxic myelodepression in patients with malignant tumors II. Phase II study of the protective effect of recombinant human interleukin-1 beta on myelodepression induced by chemotherapy in cancer patients
    Gershanovich, ML
    Filatova, LV
    Ketlinsky, SA
    Simbirtsev, AS
    EUROPEAN CYTOKINE NETWORK, 2001, 12 (04) : 671 - 675
  • [33] Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors
    Van den Wyngaert, T.
    Delforge, M.
    Doyen, C.
    Duck, L.
    Wouters, K.
    Delabaye, I.
    Wouters, C.
    Wildiers, H.
    SUPPORTIVE CARE IN CANCER, 2013, 21 (12) : 3483 - 3490
  • [34] Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors
    T. Van den Wyngaert
    M. Delforge
    C. Doyen
    L. Duck
    K. Wouters
    I. Delabaye
    C. Wouters
    H. Wildiers
    Supportive Care in Cancer, 2013, 21 : 3483 - 3490
  • [35] Recombinant Human Erythropoietin and Hemoglobin Concentration at Operation and during the Postoperative Period: Reduced Need for Blood Transfusions in Patients Undergoing Colorectal Surgery—Prospective Double-blind Placebo-controlled Study
    Niels Qvist
    Steen Boesby
    Birgit Wolff
    Carsten P. Hansen
    World Journal of Surgery, 1999, 23 : 30 - 35
  • [36] Recombinant human erythropoietin and hemoglobin concentration at operation and during the postoperative period: Reduced need for blood transfusions in patients undergoing colorectal surgery - Prospective double-blind placebo-controlled study
    Qvist, N
    Sci, D
    Boesby, S
    Wolff, B
    Hansen, CP
    WORLD JOURNAL OF SURGERY, 1999, 23 (01) : 30 - 35
  • [37] Prognostic value of circulating tumor DNA (ctDNA) detection during adjuvant chemotherapy in patients with stage III colorectal cancer: The interim report of a prospective, observational study
    Peng, Junjie
    Li, Yaqi
    Mo, Shaobo
    Ma, Xiaoji
    Hu, Xiang
    Zhang, Long
    Huang, Dan
    Cai, Sanjun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [38] PHASE-I/II STUDY, COMBINATION OF RADIOTHERAPY AND HYPERTHERMIA IN PATIENTS WITH DEEP-SEATED MALIGNANT-TUMORS - REPORT OF A PILOT-STUDY BY THE RADIATION-THERAPY-ONCOLOGY-GROUP
    EMAMI, B
    MYERSON, RJ
    SCOTT, C
    GIBBS, F
    LEE, C
    PEREZ, CA
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 20 (01): : 73 - 79
  • [39] PLASMA-LEVELS OF IL-1, TNF-ALPHA, IL-6, IL-8, G-CSF, AND IL1-RA DURING FEBRILE NEUTROPENIA - RESULTS OF A PROSPECTIVE-STUDY IN PATIENTS UNDERGOING CHEMOTHERAPY FOR ACUTE MYELOGENOUS LEUKEMIA
    SCHONBOHN, H
    SCHULER, M
    KOLBE, K
    PESCHEL, C
    HUBER, C
    BEMB, W
    AULITZKY, WE
    ANNALS OF HEMATOLOGY, 1995, 71 (04) : 161 - 168
  • [40] Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): Final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON)
    Lowenberg, B
    Suciu, S
    Archimbaud, E
    Ossenkoppele, G
    Verhoef, GEG
    Vellenga, E
    Wijermans, P
    Berneman, Z
    Dekker, AW
    Stryckmans, P
    Schouten, H
    Jehn, U
    Muus, P
    Sonneveld, P
    Dardenne, M
    Zittoun, R
    BLOOD, 1997, 90 (08) : 2952 - 2961
1234